You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

562 Results
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and No Prior Ipilimumab
New Drug Funding Program
    Pembrolizumab - Advanced Melanoma (Unresectable or Metastatic Melanoma) and Prior Ipilimumab
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
ipilimumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph, Patient Info Sheet
Mar 2026
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab and Relatlimab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab / relatlimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Gynecologic, 
Cervix
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Chemoradiotherapy for Locally Advanced Cervical Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
ODB - General Benefit
    cyclophosphamide - oral tablets
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
pegylated liposomal DOXOrubicin (Unfunded),
dexamethasone,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab (Unfunded),
trastuzumab,
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Drug
Other Name(s): Polivy™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2026
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
These evidence-based recommendations are from ColonCancerCheck, Ontario’s colorectal cancer screening program. Surveillance recommendations are...

Pages